Allied

Allied Equity

The The Equity of Allied (ALID) as of Oct 19, 2026 is -7.55 M USD. In the previous year, The Equity was -6.88 M USD — a change of 9.64% (lower).

Equity

-7.55 MUSD

YoY

9.64%

Last updated:

In 2024, Allied's equity was -7.55 M USD, a 9.64% increase from the -6.88 M USD equity in the previous year.

The Allied Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2016
-20,000.00 USD
Jan 1, 2017
-40,000.00 USD
Jan 1, 2018
-60,000.00 USD
Jan 1, 2020
3.70 M USD
Jan 1, 2021
-970,000.00 USD
Jan 1, 2022
-1.28 M USD
Jan 1, 2023
-6.88 M USD
Jan 1, 2024
-7.55 M USD
The Allied Equity history
YEAREquityYoY
-7.55 MUSD+9.64%
-6.88 MUSD+437.85%
-1.28 MUSD+31.96%
-970,000.00USD-126.22%
3.70 MUSD-6,266.67%
-60,000.00USD+50.00%
-40,000.00USD+100.00%
-20,000.00USD—
0.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Allied Stock analysis

What does Allied do? Allied Corp is a pharmaceutical company headquartered in Kelowna, British Columbia, Canada. Listed on the stock market in December 2018, the firm operates within the health care sector. It specializes in the research, development, and production of cannabinoid health solutions. Allied Corp focuses on creating medicinal cannabis and psilocybin products designed to treat various medical conditions. These potential applications include anxiety, insomnia, anorexia, chronic pain, epilepsy, chemotherapy-induced nausea and vomiting, post-traumatic stress disorder, Parkinson’s disease, Tourette syndrome, irritable bowel syndrome, and spasticity associated with multiple sclerosis and spinal cord injury. The company maintains a global operational structure through its subsidiaries. These include AM Biosciences, Allied US Products LLC, Tactical Relief LLC, Baleno Ltd., and Allied Colombia, which support its broader mission in the pharmaceutical industry. Allied is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Allied's Equity

Allied's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Allied's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Allied's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Allied's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Allied’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Allied stock

The Equity of Allied is -7.55 M USD in 2024.

The Equity of Allied changed from -6.88 M USD to -7.55 M USD, representing a 9.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Allied since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Allied historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Allied

All Key Metrics — Allied